Study Group: Generic Pharmaceuticals Economic Experts (Germany)
Council Members in this Study Group: 48
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
John Ansell, MBADirector
John Ansell Consultancy
John Ansell, MBA, has been the Director of John Ansell Consultancy, a pharmaceutical consulting firm in Thame, United Kingdom, since November 1990. Mr. Ansell has advised some 120 pharma, biotech and companies providing pharmaceutical services. He focuses on international marketing and business development...
Jan HackerManaging Partner
Oberender & PartnerJan Hacker is the Managing Partner and Co-founder of Oberender & Partner, a leading Healthcare Consulting Company in Germany. Mr. Hacker has expertise in strategic hospital management and the development of market entry strategies for foreign companies. He is also a member of the board of EconoMedic...
David SykesPrincipal
PRMA Consulting Ltd.David Sykes is the founding Partner of PRMA Consulting, United Kingdom. He is an expert in pricing, reimbursement, and health outcomes within pharmaceutical and medical device sectors. Mr. Sykes has over 14 years of blue chip experience at J&J, Lilly, and Organon within global, European and UK roles....
GLG NewsSM Analyses by this Study Group's Leading Experts (?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
A triple combination for H1N1: good in principle
October 30, 2009
John Ansell, MBA, Director, John Ansell Consultancy
Triple-combo Drug Shows Promise Against Antiviral Resistant H1N1 | www.medicalnewstoday.com
The principle behind Adamas’s triple combination development for influenza is a good one. There is clearly a need for improved treatments, as the latest wave of swine flu is now showing. Oseltamivir (Tamiflu) and ribavirin are reasonable drugs to select but the third component, amantadine, may prove...
-
GSK's new venture into Duchenne's makes sense
October 14, 2009
John Ansell, MBA, Director, John Ansell Consultancy
GlaxoSmithKline and Prosensa form alliance to fight Duchenne Muscular Dystrophy | www.pipelinereview.com
GSK's latest deal on Duchenne's muscular dystrophy with the Dutch company Prosena is a further indication of the former's interest in diversifying out of the more obvious, major areas of medicine.This can make sense: such "esoteric" indications areas are less well understood, there is less competition...
-
What does Solvay offer to a bidder ?
September 25, 2009
John Ansell, MBA, Director, John Ansell Consultancy
Sources: Abbott sparks Solvay bidding war, UCB may follow | www.fiercebiotech.com
In considering the outcome of the current bidding war, what can Solvay Pharmaceuticals offer to an acquirer ? It can’t be the R & D pipeline. In 2004 Solvay was described by one industry observer as having a great pipeline. But except for one modest short-term success in the market, all of the projects...
-
Dainippon Sumitomo acquires a bridgehead and settles Sepracor's uncertain future
September 4, 2009
John Ansell, MBA, Director, John Ansell Consultancy
Dainippon Sumitomo Pharma to Acquire Sepracor for U.S. $23.00 Per Share in an All-Cash Tender Offer Valued at Approximately U.S. $2.6 Billion | www.pipelinereview.com
In acquiring Sepracor, Dainippon Sumitomo is gaining a modest-sized commercial bridgehead for marketing its products in North America, but one which by itself had an uncertain future. Dainippon Sumitomo will need to take action to stabilize a company which has been facing issues concerning its future...
-
An important landmark for Nycomed's Daxas
September 1, 2009
John Ansell, MBA, Director, John Ansell Consultancy
Four studies published in The Lancet show roflumilast (Daxas®), a new oral approach to COPD, improves lung function and reduces exacerbations | www.nycomed.com
The level of unmet need in COPD, a very common respiratory disease, is high. Consequently, provided a new drug is registrable it does not have to have outstanding qualities to become a substantial success. Nycomed’s Daxas has recently been submitted for registration for COPD in the US and Europe....
Members in this Study Group include these company types:
- Consultancy, Pharma-Focused
- Consultancy, Healthcare-Focused
- Academic Institution*
- Pharmacy or Drug Store, Independent/Local
- Pharmaceuticals Manufacturer
- Strategic Management
- Academic Medical Center/Hospital or Clinic
- Individual/Small Consultancy
- Contract Research Organization, Independent/Small
- Drug Distributor, General or Full-Spectrum
- Law Firm (general practice/large)
- Office Based Private Practice or Clinic
- Professional or Industry Association*
Members in this Study Group often have these job titles:
- Director
- Owner
- Chief Executive Officer
- Consultant
- Principal
- President
- Project Manager
- Partner
Related Study Groups
| Study Group Name | No. Members |
|---|---|
| Generic Drug Economic Experts | 766 |
| Pharmacists in Germany | 15 |
| Biopharmaceutical Reimbursement Experts (EU) | 24 |
| Pharmacists (EU) | 184 |
| Medical Tourism Experts | 358 |
| Physicians (Germany) | 1172 |
| Generic Pharmaceuticals Regulation Experts: Healthcare Consultants | 45 |